Tumor suppressive functions of the urea cycle in renal cell carcinoma
Tumor suppressive functions of the urea cycle in renal cell carcinoma
批准号:
8835262
负责人:
Joshua D. Ochocki
金额:
$5.42万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2018-02-28
关键词:
14qAccountingAffectAgarAmino AcidsAmmoniaAnabolismArginineBiochemistryBiological AssayCarbonCell LineCellsCellular biologyCharacteristicsCitrullineClear CellClinicalDataData SetDependenceDiagnosisDiseaseDrug Metabolic DetoxicationEctopic ExpressionEnzymesExhibitsFumaratesGenesGeneticGenomicsGlucoseGlutamineGlycerophospholipidsGlycolysisGrowthHypoxia Inducible FactorImmunohistochemistryIn VitroIncidenceKidneyLiverMalignant Epithelial CellMalignant NeoplasmsMeasuresMediatingMessenger RNAMetabolicMetabolic PathwayMetabolismMethodsModelingModificationMolecularMonitorMusMutationNeoplasm MetastasisNucleotidesPathogenesisPathway interactionsPatientsPlayProteinsProto-Oncogene Proteins c-aktRadioresistanceRenal Cell CarcinomaRenal carcinomaRepressionResistanceRoleSignal TransductionStable Isotope LabelingTP53 geneTestingThe Cancer Genome AtlasTissuesTumor Suppressor GenesTumor Suppressor ProteinsWomanXenograft procedurearginaseargininosuccinate synthasebasechemotherapychromosome 14q losschromosome 3p lossglucose metabolismhuman FRAP1 proteinhypoxia inducible factor 1in vivoinhibitor/antagonistkidney celllipid metabolismmRNA Expressionmenmetabolomicsmutantnew therapeutic targetnovel therapeuticsoutcome forecastpublic health relevanceradioresistantresearch studyresponsetumortumor growthurea cycle
中文摘要
描述(申请人提供):肾透明细胞癌(CcRCC)是最常见的肾脏恶性肿瘤。它既耐化疗又耐辐射,目前对这种疾病的治疗选择有限,特别是因为每4名患者中就有1人最初被诊断为播散性、转移性疾病状态。这些临床特征的基础是分子水平上的一些变化,其中最明显的是促进恶性肿瘤的代谢变化。这些修饰之一是尿素循环,这是ccRCC中表达第二低的代谢途径。尿素循环发生在肾脏,参与游离氨的解毒。精氨酸酶II(ARG2)和精氨酸琥珀酸合成酶1(ASS1)是该周期中的两个关键酶,ARG2位于染色体14Q上,该区域的缺失与肾细胞癌的恶性程度高和预后不良有关。来自癌症基因组图谱(TCGA)数据集中的近500个原发ccRCC肿瘤的数据表明,与正常肾组织相比,ARG2在40%的ccRCC中表现出拷贝数丢失,并且在mRNA水平上低表达,而ASS1在ccRCC中显著低表达,但不是缺失。在初步实验中,我们已经证明在ccRCC细胞系中重新表达这些酶可以在体外和体内抑制异种移植瘤生长过程中的增殖。此外,ARG2和ASS1的重新表达减少了糖酵解通量,降低了mTOR活性。这一建议的中心假设是ARG2和ASS1通过调节尿素循环和糖酵解代谢以及抑制mTORC1依赖的生长途径而发挥肿瘤抑制作用。基于这一假设,我们将追求以下特定的目标:特定的目标1:确定ARG2和ASS1在介导mTORC1诱导的肾癌细胞增殖中所起的作用。目的2:探讨ARG2和ASS1基因重新表达引起的代谢改变对肾细胞癌发病机制的影响。完成这些研究将需要体外和体内方法的结合,包括生物化学、细胞生物学、免疫组织化学和代谢流量分析。本项目的目的是确定ARG2和ASS1缺失改变细胞代谢以促进ccRCC肿瘤生长的分子机制。阐明这些机制将为治疗这种疾病提供新的治疗途径。
英文摘要
DESCRIPTION (provided by applicant): Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney malignancy. It is both chemotherapy and radiation resistant and current treatment options for this disease are limited, particularly because 1 out of 4 patients are initialy diagnosed at a disseminated, metastatic disease state. Underlying these clinical characteristics are a number of changes at the molecular level, the most pronounced of which are metabolic alterations that promote malignancy. One of these modifications is to the urea cycle, which is the second most underexpressed metabolic pathway in ccRCC. The urea cycle occurs in the kidney and is involved in detoxification of free ammonia species. Two key enzymes in this cycle are arginase II (ARG2) and argininosuccinate synthase 1 (ASS1); ARG2 is included on chromosome 14q and loss of this region correlates with high malignancy grade and a poorer prognosis in ccRCC. Data from nearly 500 primary ccRCC tumors in The Cancer Genome Atlas (TCGA) dataset demonstrates that ARG2 exhibits copy number loss in 40% of ccRCC and is underexpressed at the mRNA level, whereas ASS1 is significantly underexpressed, but not deleted, in ccRCC compared to normal kidney tissue. In preliminary experiments, we have demonstrated that re-expressing these enzymes in ccRCC cell lines suppresses proliferation in vitro and in vivo during xenograft tumor growth. Furthermore, re-expression of ARG2 and ASS1 reduces glycolytic flux and decreases mTOR activity. The central hypothesis of this proposal is that ARG2 and ASS1 act as tumor suppressors by modulating urea cycle and glycolytic metabolism and by repressing mTORC1 dependent growth pathways. Based on this hypothesis, the following specific aims will be pursued: Specific Aim 1: To determine the role ARG2 and ASS1 play in mediating mTORC1 driven proliferation in ccRCC. Specific Aim 2: To determine how metabolic alterations caused by ARG2 and ASS1 re-expression influence the pathogenesis of ccRCC. Completion of these studies will require a combination of in vitro and in vivo methods that include biochemistry, cell biology, immunohistochemistry, and metabolic flux analysis. The objective of this project is to determine the molecular mechanisms by which ARG2 and ASS1 loss alters cellular metabolism to promote ccRCC tumor growth. Delineating these mechanisms will provide new therapeutic avenues to target in this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor suppressive functions of the urea cycle in renal cell carcinoma
-
批准号:9025422
-
项目类别:
-
资助金额:$2.57万
-
财政年份:2015
-
负责人:Joshua D. Ochocki
-
依托单位:
海外基金